warfarin and carvedilol

MinorWorth knowing, rarely changes the plan on its own.

Mechanism

Warfarin is metabolised primarily by CYP2C9 (S-warfarin). Carvedilol is itself partly metabolised by CYP2C9 but is not a clinically relevant CYP2C9 inhibitor, and studies have not shown a clinically significant effect of carvedilol on warfarin clearance; any bleeding risk is small and mainly pharmacodynamic in patients with additional haemostatic risk factors.

What it means clinically

The anticoagulant effect of warfarin is enhanced, leading to an increased risk of bleeding. Patients, particularly those with heart failure, may experience a rise in INR and bleeding complications such as bruising, epistaxis, or gastrointestinal haemorrhage.

What to do

Monitor INR closely when initiating, discontinuing, or changing the dose of carvedilol in patients taking warfarin. Perform a repeat INR within 3–5 days of any change and adjust the warfarin dose accordingly. Advise patients to report signs of bleeding.

Evidence

Case reports and clinical studies have demonstrated elevated INR and bleeding events. The interaction is well-recognised but the magnitude varies. Monitoring is recommended in standard practice.

The two drugs

warfarinVitamin K antagonistRead the monograph carvedilolBeta-adrenergic blockersRead the monograph

Practise prescribing around interactions like this one

Oskela marks prescriptions against this interaction database automatically: write a chart for a simulated patient and every clash is caught and explained.

Try a prescription, no account Create a free account

Other interactions involving warfarin or carvedilol

Educational reference for students and clinicians in training. It does not replace professional judgement, local protocols or current prescribing information.